Please enter your email
Send
Location:Home > Products > ADC Payload > Exatecan Mesylate
Exatecan Mesylate

CAS: 169869-90-3 (Synonyms:依喜替康甲磺酸盐)

All products are only used for scientific research, instead of human or animal experiments.


Cat. No.:HD00031

Formula:C25H26FN3O7S

Mol. Weight:531.56

Purity:≥99%

Long Term Storage:Store in a tight container at 2-8℃.

Description:DNA TOPO I inhibitor

Online Inquiry
Size Price, EXW Stock Quantity Add to Cart
10mg $185.00 In stock - 1 +
25mg $390.00 In stock - 1 +
50mg $680.00 In stock - 1 +
100mg $1150.00 In stock - 1 +
Biological Activity
Exatecan mesylate inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA and inhibiting the religation of DNA breaks, thereby inhibiting DNA replication and triggering apoptotic cell death.
Product Data
References

[1] Nakada T, Masuda T, Naito H, Yoshida M, Ashida S, Morita K, Miyazaki H, Kasuya Y, Ogitani Y, Yamaguchi J, Abe Y, Honda T. Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads. Bioorg Med Chem Lett. 2016 Mar 15;26(6):1542-5. doi: 10.1016/j.bmcl.2016.02.020. PubMed PMID: 26898815..

[2] Garrison MA, Hammond LA, Geyer CE Jr, Schwartz G, Tolcher AW, Smetzer L, Figueroa JA, Ducharme M, Coyle J, Takimoto CH, De Jager RL, Rowinsky EK. A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies. Clin Cancer Res. 2003 Jul;9(7):2527-37. PubMed PMID: 12855627..

[3] Braybrooke JP, Ranson M, Manegold C, Mattson K, Thatcher N, Cheverton P, Sekiguchi M, Suzuki M, Oyama R, Talbot DC. Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer. Lung Cancer. 2003 Aug;41(2):215-9. PubMed PMID: 12871785

Online Inquiry
Submit

You are the 145899 th Visitor

Phone:0086-571-86907218

Email:hdcsales@huidacollection.cn

Copyright © 2021 HuiDaCollection 浙ICP备20008217号 Designed by Wanhu

Back to top
Online Message
Submit